Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

56
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
56
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

50
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
50
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

245
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
245
Uncertainty in Measurement: Accuracy and Precision03:37

Uncertainty in Measurement: Accuracy and Precision

112.7K
Scientists typically make repeated measurements of a quantity to ensure the quality of their findings and to evaluate both the precision and the accuracy of their results. Measurements are said to be precise if they yield very similar results when repeated in the same manner. A measurement is considered accurate if it yields a result that is very close to the true or the accepted value. Precise values agree with each other; accurate values agree with a true value. 
112.7K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

242
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
242
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction.

Cardiovascular therapeutics·2023
Same author

Time to revisit the true role of metformin in type 2 diabetes mellitus.

Postgraduate medicine·2023
Same author

Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management.

Current heart failure reports·2023
Same author

In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients.

Postgraduate medicine·2023
Same author

Right Here and Right Now: Time to Incorporate Measures of Right Ventricular Function When Assessing Left Heart Failure Clinical Outcomes.

Journal of cardiac failure·2022
Same author

The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge.

Postgraduate medicine·2021

Related Experiment Video

Updated: Mar 7, 2026

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

8.0K

Towards Precision in HF Pharmacotherapy.

Nicholas B Norgard1, Carolyn Hempel2

  • 1University of Missouri Kansas City School of Medicine, 2411 Holmes St, Kansas City, MO, 64108, USA. norgardn@umkc.edu.

Current Heart Failure Reports
|February 13, 2017
PubMed
Summary
This summary is machine-generated.

Precision medicine offers a future for heart failure (HF) treatment by identifying distinct patient phenotypes. This approach enables targeted therapies, improving outcomes and reducing adverse drug reactions for better heart failure management.

Keywords:
Heart failurePhenomappingPrecision medicineTheranostics

More Related Videos

Accuracy in Dental Medicine, A New Way to Measure Trueness and Precision
07:57

Accuracy in Dental Medicine, A New Way to Measure Trueness and Precision

Published on: April 29, 2014

14.1K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Related Experiment Videos

Last Updated: Mar 7, 2026

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

8.0K
Accuracy in Dental Medicine, A New Way to Measure Trueness and Precision
07:57

Accuracy in Dental Medicine, A New Way to Measure Trueness and Precision

Published on: April 29, 2014

14.1K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Area of Science:

  • Cardiology
  • Genomics
  • Computational Biology

Background:

  • Heart failure (HF) presents significant heterogeneity, complicating treatment strategies.
  • Current approaches often treat HF as a uniform condition, overlooking diverse pathophysiologies.
  • Developing targeted therapies requires precise identification of HF subtypes.

Purpose of the Study:

  • To explore the future of precision medicine in heart failure (HF) treatment.
  • To highlight the need for identifying distinct HF phenotypes for personalized therapy.
  • To review methods for phenotyping HF patients.

Main Methods:

  • Utilizing phenomapping with machine learning algorithms on clinical datasets.
  • Analyzing genetic, epigenetic, proteomic, and metabolomic data for comprehensive profiling.
  • Identifying patient subgroups with differential treatment responses.

Main Results:

  • Phenomapping successfully identified distinct, clinically meaningful HF groups.
  • Future analyses promise more comprehensive phenotypic profiles.
  • Identifying responsive patient profiles can guide optimal therapy selection.

Conclusions:

  • Precision medicine, driven by advanced phenotyping, is crucial for advancing HF treatment.
  • Tailoring therapies to specific HF phenotypes will improve patient outcomes.
  • This approach minimizes trial-and-error prescribing and reduces adverse drug reactions.